Details of subjects affected by thromboembolism in the follow-up period
Patient no. . | Age, y . | Sex . | Ig isotype (G or M) . | Time lag,* y . | Primary prophylaxis . | Type of event . |
---|---|---|---|---|---|---|
1 | 13 | Female | G | 5.4 | ASA | Stroke† |
2 | 61 | Male | G | 0.9 | — | Stroke† |
3 | 24 | Female | G | 18.4 | ASA | Renal thrombotic microangiopathy |
4 | 56 | Female | G | 2.5 | — | Proximal DVT |
5 | 54 | Male | G | 4 | ASA | Proximal DVT |
6 | 25 | Female | G | 1.8 | — | Stroke† |
7 | 43 | Female | G | 1.5 | — | Proximal DVT |
8 | 30 | Female | G | 2.6 | — | PE |
9 | 33 | Female | G | 2 | — | Stroke† |
10 | 54 | Male | G | 4 | — | Stroke† |
11 | 22 | Male | M | 1.2 | — | Proximal DVT + PE |
12 | 57 | Female | G | 2.1 | — | Myocardial infarction |
13 | 48 | Male | G | 2.4 | — | Stroke† |
14 | 44 | Female | G | 3.1 | — | Proximal DVT + PE |
15 | 38 | Male | G | 1.8 | — | Proximal DVT |
16 | 50 | Male | G | 1 | — | Proximal DVT + PE |
17 | 40 | Male | G | 3 | — | PE |
18 | 65 | Female | G | 9 | — | TIA† |
19 | 22 | Female | G | 1.7 | — | Right atrial thrombosis |
20 | 57 | Female | G | 5 | ASA | TIA† |
21 | 41 | Female | M | 11.5 | ASA | Retinal artery thrombosis |
22 | 55 | Female | G | 4.8 | — | Proximal DVT |
23 | 45 | Female | M | 2 | ASA | Proximal DVT |
24 | 53 | Female | G | 3.2 | ASA | Stroke† |
25 | 31 | Female | G | 2.8 | — | Stroke† |
Patient no. . | Age, y . | Sex . | Ig isotype (G or M) . | Time lag,* y . | Primary prophylaxis . | Type of event . |
---|---|---|---|---|---|---|
1 | 13 | Female | G | 5.4 | ASA | Stroke† |
2 | 61 | Male | G | 0.9 | — | Stroke† |
3 | 24 | Female | G | 18.4 | ASA | Renal thrombotic microangiopathy |
4 | 56 | Female | G | 2.5 | — | Proximal DVT |
5 | 54 | Male | G | 4 | ASA | Proximal DVT |
6 | 25 | Female | G | 1.8 | — | Stroke† |
7 | 43 | Female | G | 1.5 | — | Proximal DVT |
8 | 30 | Female | G | 2.6 | — | PE |
9 | 33 | Female | G | 2 | — | Stroke† |
10 | 54 | Male | G | 4 | — | Stroke† |
11 | 22 | Male | M | 1.2 | — | Proximal DVT + PE |
12 | 57 | Female | G | 2.1 | — | Myocardial infarction |
13 | 48 | Male | G | 2.4 | — | Stroke† |
14 | 44 | Female | G | 3.1 | — | Proximal DVT + PE |
15 | 38 | Male | G | 1.8 | — | Proximal DVT |
16 | 50 | Male | G | 1 | — | Proximal DVT + PE |
17 | 40 | Male | G | 3 | — | PE |
18 | 65 | Female | G | 9 | — | TIA† |
19 | 22 | Female | G | 1.7 | — | Right atrial thrombosis |
20 | 57 | Female | G | 5 | ASA | TIA† |
21 | 41 | Female | M | 11.5 | ASA | Retinal artery thrombosis |
22 | 55 | Female | G | 4.8 | — | Proximal DVT |
23 | 45 | Female | M | 2 | ASA | Proximal DVT |
24 | 53 | Female | G | 3.2 | ASA | Stroke† |
25 | 31 | Female | G | 2.8 | — | Stroke† |
— indicates no primary prophylaxis; ASA, aspirin 100 mg 4 times a day; DVT, deep vein thrombosis; PE, pulmonary embolism; and TIA, transient ischemic attack.
Time interval from laboratory finding to the thromboembolic event.
All the clinical events had a pertinent area of ischemia at cerebral imaging.